Abstract
At least three renal tubular segments are involved in the pathophysiology of salt-losing tubulopathies (SLTs). Whether the pathogenesis starts either in the thick ascending limb of the loop of Henle (TAL) or in the distal convoluted tubule (DCT), it is the function of the downstream-localized aldosterone sensitive distal tubule (ASDT) to contribute to the adaptation process. In isolated TAL defects (loop disorders) ASDT adaptation is supported by upregulation of DCT, whereas in DCT disorders the ASDT is complemented by upregulation of TAL function. This upregulation has a major impact on the clinical presentation of SLT patients. Taking into account both the symptoms and signs of primary tubular defect and of the secondary reactions of adaptation, a clinical diagnosis can be made that eventually leads to an appropriate therapy. In addition to salt wasting, as occurs in all SLTs, characteristic features of loop disorders are hypo- or isosthenuric polyuria and hypercalciuria, whereas characteristics of DCT disorders are hypokalemia and (symptomatic) hypomagnesemia. In both SLT categories, replacement of urinary losses is the primary goal of treatment. In loop disorders COX inhibitors are also recommended to mitigate polyuria, and in DCT disorders magnesium supplementation is essential for effective treatment. Of note, the combination of a salt- and potassium-rich diet together with an adequate fluid intake is always the basis of long-term treatment in all SLTs.
References
Ellison DH (2012) Adaption in Gitelman syndrome: „we just want to pump you up“. Clin J Am Soc Nephrol 7:379–382
Seyberth HW, Schlingmann KP (2011) Bartter- and Gitelman-like syndromes: salt-losing tubulopathies with loop or DCT defects. Pediatr Nephrol 26:1789–1802
Zeidel ML, Hoenig MP, Palevsky PM (2014) A new CJASN series: renal physiology for the clinician. Clin J Am Soc Nephrol 9:1271
Hoenig MP, Zeidel ML (2014) Homeostasis, the milieu intérieur, and the wisdom of the nephron. Clin J Am Soc Nephrol 9:1272–1281
Mount DB (2014) Thick ascending limb of the loop of Henle. Clin J Am Soc Nephrol 9:1974–1986
Subramanya AR, Ellison DH (2014) Distal convoluted tubule. Clin J Am Soc Nephrol 9:2147–2163
Pearce D, Soundararajan R, Trimpert C, Kashlan OB, Deen PM, Kohan DE (2015) Collecting duct principal cell transport processes and their regulation. Clin J Am Soc Nephrol 10:135–146
Roy A, Al-Bataineh MM, Pastor-Soler NM (2015) Collecting duct intercalated cell function and regulation. Clin J Am Soc Nephrol 10:305–324
Cheng CJ, Sung CC, Huang CL, Lin SH (2015) Inward-rectifying potassium channelopathies: new insights into disorders of sodium and potassium homeostasis. Pediatr Nephrol 30:373–383
Luke RG, Galla JH (2012) It is chloride depletion alkalosis, not contration alkalosis. J Am Soc Nephrol 23:204–207
Olesen ET, Fenton RA (2013) Is there a role for PGE2 in urinary concentration? J Am Soc Nephrol 24:169–178
Bockenhauer D, Bichet DG (2013) Inherited secondary nephrogenic diabetes insipidus: concentrating on humans. Am J Physiol Ren Physiol 304:F1037–F1042
van der Wijst J, Bindels RJ, Hoenderop JG (2014) Mg2+ homeostasis: the balancing act of TRPM6. Curr Opin Nephrol Hypertens 23:361–369
Chaimovitz C, Levi J, Better OS, Oslander L, Benderli A (1973) Studies on the site of renal salt loss in a patient with Bartter’s syndrome. Pediatr Res 7:89–94
Uribarri J, Alveranga D, Oh MS, Kukar NM, Del Monte ML, Carroll HJ (1985) Bartter’s syndrome due to a defect in salt reabsorption in the distal convoluted tubule. Nephron 40:52–56
Köckerling A, Reinalter SC, Seyberth HW (1996) Impaired response to furosemide in hyperprostaglandin E syndrome: evidence for a tubular defect in the loop of Henle. J Pediatr 129:519–528
Unwin RJ, Capasso G (2006) Bartter’s and Gitelman’s syndromes: their relationship to the actions of loop and thiazide diuretics. Curr Opin Pharmacol 6:208–213
Reinalter SC, Jeck N, Peters M, Seyberth HW (2004) Pharmacotyping of hypokalaemic salt-losing tubular disorders. Acta Physiol Scand 181:513–521
Seyberth HW (2008) An improved terminology and classification of Bartter-like syndromes. Nat Clin Pract Nephrol 4:560–567
Chadha V, Alon US (2009) Hereditary renal tubular disorders. Semin Nephrol 29:399–411
Nozu K, Iijima K, Kanda K, Nakanishi K, Yoshikawa N, Satomura K, Kaito H, Hashimura Y, Ninchoji T, Komatsu H, Kamei K, Miyashita R, Kugo M, Ohashi H, Yamazaki H, Mabe H, Otsubo A, Igarashi T, Matsuo M (2010) The pharmacological characteristics of molecular-based inherited salt-losing tubulopathies. J Clin Endocrinol Metab 95:E511–E518
Cruz AJ, Castro A (2013) Gitelman or Bartter type 3 syndrome? A case of distal convoluted tubulopathy caused by CLCNKB gene mutation. BMJ Case Rep. doi:10.1136/bcr-2012-007929
Nüsing RM, Schaub TP, Klein T, Schweer H, Seyberth HW (1997) Prostanoid biosynthesis by blood monocytes of children with hyperprostagandin E syndrome. Pediatr Res 42:241–246
Seyberth HW, Rascher W, Schweer H, Kühl PG, Mehls O, Schärer K (1985) Congentital hypokalemia with hypercalciuria in pretem infants: a hyperprostaglandinuric tubular syndrome different from Bartter syndrome. J Pediatr 107:694–701
Jeck N, Schlingmann KP, Reinalter SC, Kömhoff M, Peters M, Waldegger S, Seyberth HW (2005) Salt handling in distal nephron: lessons learned from inherited human disorders. Am J Physiol Regul Integr Comp Physiol 288:R782–R795
Knepper MA, Kwon TH, Nielsen S (2015) Molecular physiology of water balance. N Engl J Med 372:1349–1358
Peters M, Jeck N, Reinalter S, Leonhardt A, Tönshoff B, Klaus G, Gü KM, Seyberth HW (2002) Clinical presentation of genetically defined patients with hypokalemic salt-losing tubulopathies. Am J Med 112:183–190
Simon DB, Bindra RS, Mansfield TA, Nelson-Williams C, Mendonca E, Stone R, Schurman S, Nayir A, Alpay H, Bakkaloglu A, Rodriguez-Soriano J, Morales JM, Sanjad SA, Taylor CM, Pilz D, Brem A, Trachtman H, Griswold W, Richard GA, John E, Lifton RP (1997) Mutations of the chloride channel gene, CLCNKB, cause Bartter’s syndrome type III. Nat Genet 17:171–178
Konrad M, Vollmer M, Lemmink HH, van den Heuvel LP, Jeck N, Vargas- Poussou R, Lakings A, Ruf R, Deschênes G, Antignac C, Guay-Woodford L, Knoers NV, Seyberth HW, Feldmann D, Hildebrandt F (2000) Mutations in the chloride channel gene CLCNKB as a cause of classic Bartter syndrome. J Am Soc Nephrol 11:1449–1459
Krämer BK, Bergler T, Stoelcker B, Waldegger S (2008) Mechanisms of disease: kidney-specific chloride channels ClCKA and ClCKB, Barttin subunit; and their clinical relevance. Nat Clin Pract Nephrol 4:38–46
Ellison DH (1991) The physiologic basis of diuretic synergism: its role in treating diuretic resistance. Ann Intern Med 114:886–894
Hoorn EJ, Ellison DH (2012) WNK kinases and the kidney. Exp Cell Res 318:1020–1026
Moes AD, van der Lubbe N, Zietse R, Loffing J, Hoorn EJ (2014) The sodium chloride cotransporteter SLC12A3: new roles in sodium, potasium, and blood pressure regulation. Pflugers Arch 466:107–118
Huang CL, Kuo E (2007) Mechanism of hypokalemia in magnesium deficiency. J Am Soc Nephrol 18:2649–2652
Liu W, Pastor-Soler NM, Schreck C, Zavilowitz B, Kleyman TR, Satlin LM (2012) Luminal flow modulates H+-ATPase activity in cortical collecting duct (CCD). Am J Physiol Ren Physiol 302:F205–F215
Liu Y, Flores D, Carrisoza-Gaytán R, Rohatgi R (2014) Biochemical regulation of cyclooxygenase-2 in the renal collecting duct. Am J Physiol Ren Physiol 306:F214–F223
Colussi G, Bettinelli A, Tedeschi S, De Ferrari ME, Syrén ML, Borsa N, Mattiello C, Casari G, Bianchetti MG (2007) A thiazide test for the diagnosis of renal tubular hypokalemic disorders. Clin J Am Soc Nephrol 2:454–460
van Angelen AA, van der Kemp AMW, Hoenderop JG, Bindels RJ (2012) Increased expression of renal TRPM6 compensates for Mg2+ wasting during furosemide treatment. Clin Kidney J 5:535–544
Favre GA, Nau V, Kolb I, Vargas-Poussou R, Hannedouche T, Moulin B (2012) Localization of tubular adaptation to renal sodium loss in Gitelman syndrome. Clin J Am Soc Nephrol 7:472–478
Brochard K, Boyer O, Blanchard A, Loirat C, Niaudet P, Macher MA, Deschenes G, Bensman A, Decramer S, Cochat P, Morin D, Broux F, Caillez M, Guyot C, Novo R, Jeunemaître X, Vargas-Poussou R (2009) Phenotype- genotype correleation in antenatal and neonatal variants of Bartter syndrome. Nephrol Dial Transplant 24:1455–1464
Kömhoff M, Tekesin I, Peters M, Leonhard A, Seyberth HW (2005) Perinatal management of a preterm neonate affected by hyperprostaglandin E2 syndrome (HPS). Acta Paediatr 94:1690–1693
Leonhardt A, Timmermanns G, Roth B, Seyberth HW (1992) Calcium homeostasis and hypercalciuria in hyperprostaglandin E syndrome. J Pediatr 120:546–554
Reinalter SC, Gröne HJ, Konrad M, Seyberth HW, Klaus G (2001) Evaluation of long-term treatment with indomethacin in hereditary hypokalemic salt-losing tubulopathies. J Pediatr 139:398–406
Reinalter S, Devlieger H, Proesmans W (1998) Neonatal Bartter syndrome: sponataneous resolution of all signs and symptoms. Pediatr Nephrol 12:186–188
Ishimori S, Kaito H, Matsunoshita N, Otsubo H, Hashimoto F, Ninchoji T, Nozu K, Morisada N, Iijima K (2013) SLC26A3 gene analysis in patients with Bartter and Gitleman syndromes and clinical characteristics of patients with unidentified mutations. Kobe J Med Sci 59:E36–E43
Cruz DN, Shaer AJ, Bia MJ, Lifton RP, Simon DB, Yale Gitelman's and Bartter's Syndrome Collaborative Study Group (2001) Gitelman’s syndrome revisited: an evaluation of symptoms and health-related qualitity of life. Kidney Int 59:710–717
Blanchard A, Vargas-Poussou R, Vallet M, Caumont-Prim A, Allard J, Desport E, Dubourg L, Monge M, Bergerot D, Baron S, Essig M, Bridoux F, Tack I, Azizi M (2015) Indomethacin, amiloride, or eplerenone for treating hypokalemia in Gitelman syndrome. J Am Soc Nephrol 26:468–475
Brown NJ (2013) Contribution of aldosterone to cardiovascular and renal inflammation and fibrosis. Nat Rev Nephrol 9:459–469
Bockenhauer D, Cruwys M, Kleta R, Halperin LF, Wildgoose P, Souma T, Nukiwa N, Cheema-Dhadli S, Chong CK, Kamel KS, Davids MR, Halperin ML (2008) Antenatal Bartter’s syndrome: why ist this not a lethal condition? QJM 101:927–942
Famularo G, Gasbarrone L, Minisola G (2013) Hypomagnesemia and proton- pump inhibitors. Expert Opin Drug Saf 12:709–716
Bartter FC, Pronove P, Gill JR Jr, MacCardle RC (1962) Hyerplasia of the juxtaglomerular complex with hyperaldosteronism and hypokalemic alkalosis. A new syndrome. Am J Med 33:811–828
Gitelman HJ, Graham JB, Welt LG (1966) A new familie disorder characterized by hypokalemia and hypomagnesemia. Trans Assoc Am Phys 79:221–235
McCredie DA, Rotenberg E, Williams AL (1974) Hypercalciuria in potassium-losing nephropathy: a new variant of Bartter’s syndrome. Aust Paediatr J 10:286–295
Conflict of interest
The author declares no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Additional information
Answers
1: C. For the boy, the DC1 type of SLT is the most likely diagnosis based on the combination of tetany with normal urine osmolality after dehydration. For the adult, the combination of tetany with isothenuria and hypochloremia best fits the diagnosis of a tubular disorder of the DC2 type. A loop disorder can definitely be excluded.
2: B. The triad of hypokalemia, hypomagnesemia, and almost normal specific gravity in a random urine specimen is characteristic for a DCT-like disorder in all three patients. However, the additional sign of hypochloremia in the unrelated young woman leads to the diagnosis of a DC2 type disorder.
3: A. Children with hypercalciuria and potassium-losing nephropathy fulfill all of the critical criteria for the diagnosis of a loop disorder, particularly when they had been born prematurely after a pregnancy that had been complicated by polyhydramnios. As hypokalemia was not necessarily present when the infants were first examined, one can assume that the most likely diagnosis is a L2 type disorder with ROMK defect. This SLT type is often associated with transient hypoaldosteronism in the postnatal period.
4: B. The (additional) function of ClC-Ka can be best demonstrated by comparing the clinical presentation of patients with isolated ClC-Kb defect (DC2 type) directly with the presentation of patients with a combined ClC-Ka and ClC-Kb defect (L-DC1 type).
5: E. Na-K-ATPase is the only functional protein that is expressed at the basolateral and not at the apical/luminal cell membrane. Therefore it cannot be stimulated directly by increased urine flow.
Rights and permissions
About this article
Cite this article
Seyberth, H.W. Pathophysiology and clinical presentations of salt-losing tubulopathies. Pediatr Nephrol 31, 407–418 (2016). https://doi.org/10.1007/s00467-015-3143-1
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00467-015-3143-1